Provided by Tiger Trade Technology Pte. Ltd.

Apollomics Inc

25.00
+0.67312.77%
Volume:515
Turnover:12.37K
Market Cap:54.90M
PE:-3.30
High:25.00
Open:25.00
Low:25.00
Close:24.33
52wk High:42.12
52wk Low:3.66
Shares:2.20M
Float Shares:634.70K
Volume Ratio:0.06
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.5700
EPS(LYR):-7.5700
ROE:-1305.37%
ROA:-57.61%
PB:-17.22
PE(LYR):-3.30

Loading ...

Apollomics CEO Chen Hung-Wen Reports Purchase of $7,450,008 Class a Shares

Reuters
·
Aug 18

Apollomics Umumkan Private Placement USD 10 Juta Lewat Penjualan 533.334 Saham Kelas a Tak Terdaftar

Reuters
·
Aug 12

Apollomics Announces $10 Million Private Placement Transaction

THOMSON REUTERS
·
Aug 12

Apollomics Files Form 3 as Director Yen Hung Hsien Reports Beneficial Ownership

Reuters
·
Jul 25

Apollomics Appoints Hung-hsien Yen to Board After Two Directors Resign

Reuters
·
Jul 22

Apollomics Inc trading halted, volatility trading pause

TIPRANKS
·
Jul 17

NASDAQ Trade Halt Volatility Trading Pause at 09:47 Am

Reuters
·
Jul 17

Apollomics Regains NASDAQ Compliance with $35 Million Market Value Requirement

Reuters
·
Jul 13

Apollomics Regains Full Compliance with NASDAQ Listing Requirements

THOMSON REUTERS
·
Jul 13

Apollomics Inc trading resumes

TIPRANKS
·
Jun 26

NASDAQ Trade Halt Volatility Trading Pause at 11:50 Am

Reuters
·
Jun 25

Apollomics Initiates Dispute Process with Launxp over Unpaid $3.8 Million Vebreltinib License Fee

Reuters
·
Jun 25

Apollomics: Termination Due to Launxp's Failure to Cure Material Breach of Its Obligations Under Agreement

THOMSON REUTERS
·
Jun 25

Apollomics: Formally Initiated Dispute Resolution Process on June 18 Related Top Launxp International Agreement Termination

THOMSON REUTERS
·
Jun 25

Apollomics receives noncompliance notice from Nasdaq

TIPRANKS
·
Jun 25

Apollomics Inc: Effective June 11, Formally Terminated Its Collaboration and License Agreement with Launxp International

THOMSON REUTERS
·
Jun 25

Apollomics - Regains Rights to Vebreltinib (apl-101) in Asia

THOMSON REUTERS
·
Jun 25

Apollomics Gets NASDAQ Notice for Falling Below $35 Million Market Value Minimum

Reuters
·
Jun 25

Press Release: Apollomics Receives NASDAQ Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (apl-101) in Asia

Dow Jones
·
Jun 25

Press Release: Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Dow Jones
·
Apr 27